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Abstract: Tissue regeneration into a three-dimensional scaffold requires the stimulation of blood vessel
ingrowth. We have employed a freely interconnecting porous scaffold developed by us to determine the
utility of a covalently bound heparin surface coating for the delivery of vascular endothelial growth factor
(VEGF) and platelet-derived growth factor BB (PDGF-BB) in vivo. The heparin surface was shown to
release VEGF far more rapidly than PDGF-BB in vitro (VEGF: 75 ng/h for 24 h; PDGF-BB: 86 pg/h for
>7 days). In rat subcutaneous implants, at 10 days the heparin surface alone increased vessel ingrowth
substantially (p<0.05 vs. unmodified scaffold), release of VEGF resulted in a further increase (p<0.05
vs. heparinized scaffold), whereas PDGF-BB had no additional effect. The increase induced by the
combination of growth factors was similar to VEGF alone. After 2 months, PDGF-BB, but not VEGF
delivery, resulted in a substantial increase in vascularization above that induced by heparin (p<0.05).
At the longer time point the combination of growth factors was similar to PDGF-BB. However, only
the combination of growth factors significantly elevated the number of ingrowing arterioles (p<0.05 vs.
heparinized scaffold). Thus, the covalent modification of a porous scaffold with heparin allows for the
differential release of VEGF and PDGF-BB that results in both a rapid and sustained increase in scaffold
vascularization.
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Sustaining Neovascularization of a Scaffold Through
Staged Release of Vascular Endothelial Growth Factor-A
and Platelet-Derived Growth Factor-BB
Neil H. Davies, Ph.D.,* Christian Schmidt, Ph.D., M.D.,*,{ Deon Bezuidenhout, Ph.D.,
and Peter Zilla, Ph.D., M.D.
Tissue regeneration into a three-dimensional scaffold requires the stimulation of blood vessel ingrowth. We have
employed a freely interconnecting porous scaffold developed by us to determine the utility of a covalently
bound heparin surface coating for the delivery of vascular endothelial growth factor (VEGF) and platelet-derived
growth factor BB (PDGF-BB) in vivo. The heparin surface was shown to release VEGF far more rapidly than
PDGF-BB in vitro (VEGF: 75 ng/h for 24 h; PDGF-BB: 86 pg/h for > 7 days). In rat subcutaneous implants, at 10
days the heparin surface alone increased vessel ingrowth substantially ( p < 0.05 vs. unmodified scaffold), release
of VEGF resulted in a further increase ( p < 0.05 vs. heparinized scaffold), whereas PDGF-BB had no additional
effect. The increase induced by the combination of growth factors was similar to VEGF alone. After 2 months,
PDGF-BB, but not VEGF delivery, resulted in a substantial increase in vascularization above that induced by
heparin ( p < 0.05). At the longer time point the combination of growth factors was similar to PDGF-BB. However,
only the combination of growth factors significantly elevated the number of ingrowing arterioles ( p < 0.05 vs.
heparinized scaffold). Thus, the covalent modification of a porous scaffold with heparin allows for the
differential release of VEGF and PDGF-BB that results in both a rapid and sustained increase in scaffold
vascularization.
Introduction
The successful replacement of nonfunctional tissue viaguided in situ regeneration into a three-dimensional (3D)
scaffold requires the concomitant formation of a neovascu-
lature to supply the cells within the newly formed tissue
with oxygen and nutrients. The new network will need to be
established rapidly and to persist; in most instances, it is
envisaged that neovascularization will be achieved through
angiogenesis. The exogenous delivery of growth factors1,2 is
the most widely investigated means of stimulating angio-
genesis. In 3D scaffold-based tissue regeneration it is most
sensible that the growth factors be delivered from the im-
planted scaffold, as this should generate a gradient of the
factors, thus stimulating vessel growth towards the desired
site.2 However, it has become increasingly clear that there are
a number of additional critical design requirements for ef-
fective delivery of pro-angiogenic growth factors from scaf-
folds. These include the need to sustain delivery over an
extended period (weeks to months) to allow for the possi-
bility of stable neovessel network generation3,4 and to avoid
the potential safety concerns of bolus delivery of large doses
of growth factors (e.g., vascular endothelial growth factor
[VEGF] has been reported to produce hemangiomas).5 As a
corollary to the above, the scaffold should also sequester the
factors away from the cellular milieu, as the half-lives of
factors can be very short when they are in solution in vivo,
with that of basic fibroblast growth factor (bFGF) and VEGF
being less than 1 h after intravenous injection.6,7
Furthermore, an ability to deliver combinations of growth
factors is desirable, as though single factor delivery has been
shown to be angiogenic, the results of clinical trials that re-
sulted from this research have been disappointing.8 It is now
generally supposed that this lack of efficacy resulted in part
from an initial under appreciation of the complexity of the
angiogenic process9,10 whereby there is interplay between a
number of angiogenic factors in creating a stable, functional
vascular network. Recently, the delivery of bFGF and
platelet-derived growth factorplatelet-derived growth factor
(PDGF) was shown to generate long-lasting vascular sys-
tems (> 1 year), whereas VEGF, bFGF, and PDGF alone did
not.9 Coincident to the ability to deliver growth factor
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combinations is the capacity to stage their delivery to more
closely simulate that that occurs physiologically. Staged de-
livery of VEGF followed by PDGF-BB from blown PLGA/
PLG foam/bead composites resulted in stable vasculature
being formed for up to 4 weeks after implantation.11
Physiologically, growth factors are found to bind to gly-
cosaminoglycans (e.g., heparan sulfate and heparin) and
extracellular matrix proteins (e.g., collagen and fibronec-
tin).12. This presumably serves in part to prolong their du-
ration; thus, the utilization of these types of molecules as
delivery vehicles for growth factors has begun to be explored
in the field of therapeutic angiogenesis.2 Heparin has been
shown to bind a large array of growth factors and accord-
ingly heparin has been conjugated to biopolymers in the
form of hydrogels, porous scaffolds, and fibers to immobilize
factors such as VEGF, basic fibroblast growth, PDGF-BB, and
keratinocyte growth factor.13–15 These derivatized scaffolds
were shown to influence cellular and vessel growth after
implantation.
We have developed a scaffold with well-defined inter-
connected porosity that allows for quantitative analysis of
vessel ingrowth into the scaffold.4,16–18 Covalent coupling of
heparin to the porous surface was found to be inherently
pro-angiogenic. In the current study we utilized this system
to characterise the binding of VEGF and PDGF-BB to the
heparinized surface and the ability of this combination to




VEGF165 was produced as described in detail previously.
4
In brief, human VEGF165 was expressed in Escherichia coli
expression host BL21 (DE3) pLysS. After lysis, solubilization
in urea, and dimerization, the dimeric protein was purified
on a heparin agarose affinity column.
Human PDGF-BB was purchased from PeproTech, Inc.
(Rocky Hill, NJ).
Production and heparin surface modification
of porous polyurethane
Polyurethane (PU) discs with a diameter of 5.4mm and a
thickness of 2mm with well-defined open porosity (82%
porosity, 157– 1mm pores) were produced by a variation on
the phase inversion/porogen extraction technique, as de-
scribed previously17 (Fig. 1). In brief, tubular moulds were
pre-packed with gelatin beads and the interstices infiltrated
with PU solution. After demolding, polymer precipitation,
and porogen removal by extensive washing in water, the
resultant porous cylinders were dried and sliced into discs.
Details of the covalent heparinization of the porous discs
have also been previously described.16 Briefly, PU discs were
surface-grafted by cerium-ion initiated copolymerization
with acrylic acid and acrylamide, aminated by reaction with
ethylene diamine after carbodiimide activation of the car-
boxylic acid groups, and heparinized by reductive amination
using nitrous acid de-aminated heparin.
Treated PU discs were rinsed in distilled water, washed
overnight in phosphate-buffered saline (PBS, pH 7.4), steril-
ized by immersion in 70% ethanol for 12 h, and air-dried
under sterile conditions until loading with growth factors.
Growth factor elution
Either VEGF (12 mg)19 or PDGF-BB (1.8 mg), or combination
thereof, was allowed to passively adsorb overnight onto the
heparinized surface at 4C. Non-heparin-coated or heparin
coated PU control discs were loaded with 40mL of PBS in the
same manner and left overnight at 4C.
The discs (four replicates per group) were then individu-
ally washed three times at 37C (15min each) and the growth
factor present in the washes quantified. Each disc was then
placed in 10mL PBS (equivalent to 200· volumes of a single
disc) at 37C and constantly agitated, and aliquots were
taken across 8 days. Discs were then placed in PBS con-
taining 1M NaCl (high salt elution). VEGF and PDGF-BB
content was assayed with growth factor-specific ELISA
(R&D, Minneapolis, MN).
In vivo angiogenesis assay
All animal experiments were approved by the Animal
Research and Ethics Committee of the University of Cape
Town and were in compliance with the Principles of La-
boratory Care and the guidelines for the care and use of
laboratory animals (NIH publication no. 86–23). After anes-
thesia (ketamine/xylazine) and shaving of the animal, 1 cm
longitudinal incisions were made through the skin at either
side of the dorsal midline and a subcutaneous pocket for
each disc was prepared by gentle blunt dissection (using
aseptic technique). The discs were implanted with each rat
(Wistar) receiving only one disc of each group (eight rats
were utilized per time point resulting in eight disc replicates
per group), and the skin incisions were closed with single 3/
0 Prolene sutures. After 10 days or 2 months days of
FIG. 1. Scanning electron
micrographs of cross sections
of uncoated (A) and heparin-
coated (B) porous PU discs.
The rough appearance of the
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implantation, the animals were sacrificed by inhalation of
carbon dioxide. Discs were explanted with their surrounding
capsules, halved into equal semi-cylindrical sections, and
fixed (one half of each disc fixed in zinc fixative20 and the
other in 10% buffered formalin) for 24 h before both were
transferred to a 70% EtOH solution before processing.
Immunohistochemistry
After fixation in zinc or 10% formalin fixative, all samples
were processed through graded alcohol and then embedded
in paraffin wax. Cross sections (3mm thick) from the
mid-region of the device were dewaxed with 2,2,4-tri-
methylpentane. For detection of blood vessels, zinc-fixed
sections were incubated with a 1:50 dilution of mouse anti-
rat CD31 primary antibody (RDI Research Diagnostics, Inc.,
Flanders, NJ) in 1% bovine serum albumin ( Jacksons Im-
munoresearch, West Grove, PA) in PBS. The primary anti-
body was then detected with a mouse on rat alkaline
phosphatase-polymer kit (Biocare Medical, Concord, CA) as
per manufacturer’s instructions. For detection of mural cells,
formalin-fixed sections were incubated with a 1:25 dilution
of mouse anti-rat a-smooth muscle cell actin (a-SMC actin;
Fitzgerald Industries International, Acton, MA) in PBS. The
primary antibody was then detected with a 1:250 dilution of
an Alexa488 conjugated goat anti-mouse secondary antibody
( Jackson Immunoresearch).
Histological analysis
CD31-stained samples were loaded into a Nikon Cool-
scope (Nikon Corp., Tokyo, Japan), and an image of the
complete mid region cross-section was acquired at a 100·
magnification (thus, a micrograph was generated that en-
compasses a 5.4 · 2mm cross section for each replicate). All
of the ensuing analysis was performed with Visiopharm
Integrated Systems (Visiopharm A/S, Hørsholm, Denmark).
Briefly, the software was trained to automatically detect CD31-
positive structures; all analyses were assessed by an observer
for accuracy (presence of a lumen was prerequisite in assigning
staining to vasculature) and, if necessary, manually corrected.
Vascular area of each vessel was defined as the area occupied
by both the endothelium and lumen. Vascular area and vessel
number were normalized to total ingrowth area. Total in-
growth area was extrapolated from gravimetric determination
of the volume of disc occupied by PU scaffold, namely, 18%.16
The heparin coating does not significantly decrease available
ingrowth area.16 Vascular area is given as the percentage of
ingrowth area occupied by vessels, whereas vessel density is
given as number of vessels per mm2 of ingrowth area.
SMC actin-stained sections were imaged on a Nikon 90i
fluorescence microscope (Nikon Corp.) at 40· magnification
and an entire cross-sectional area was captured using the
stitching facility in the Nikon software. SMC actin-positive
cells were automatically detected using Visiopharm software.
Statistical analysis
For quantitative analysis, one-way analysis of variance
was performed when more than two groups were compared
and two-tailed student t-tests were used to assess differences
between two groups. p< 0.05 was considered significant.
Data are expressed as mean values – standard error.
Results
Release kinetics of VEGF and PDGF-BB
from heparinized porous PU
There was a substantial difference in both the binding and
elution of VEGF and PDGF-BB to the heparinized PU (Fig. 2).
Initial washing eluted 72% (– 13%) of loaded VEGF, a further
16% (– 1%) eluted over approximately 24 h with a nominal
rate of 75 ng/h (– 0.026 ng/h). Only 1% of VEGF loaded was
detected in the high salt displacement eluant. For PDGF-BB,
only 1% of loaded growth factor could be detected in the pre-
wash eluant and a further 0.9% (– 0.1%) was eluted over 7
days at a nominal rate of 86 pg/h ( – 0.11 pg/h). Half
(50% – 1%) of the remaining PDGF-BB was eluted with high
salt. There were no significant differences in the amount of
relative growth factor eluted at the various time points for
single or dual growth factor-loaded heparinized PU.
Neovascularization after subcutaneous implantation
of heparinized porous PU for 10 days
The ingrowth of vessels into unmodified PU discs (Fig. 3)
was similar in nature to that previously observed for tubular
FIG. 2. Elution profiles of VEGF and PDGF-BB from hep-
arin-modified PU discs at 37C over 8 days. (A) Elution of
VEGF from discs loaded with VEGF alone (circles) and with
VEGF and PDGF-BB (squares). (B) Elution of PDGF-BB from
discs loaded with PDGF-BB alone (circles) and with VEGF
and PDGF-BB (squares) (n = 4). VEGF, vascular endothelial
growth factor; PDGF-BB, platelet-derived growth factor BB.
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FIG. 3. Vascularization





uncoated PU discs (A) and
heparin-coated PU discs (B)
and heparin-coated discs
loaded with VEGF (C) or
VEGF and PDGF-BB (D) (bar
represents 50 mm). Vessel
ingrowth was quantified for
both vessel density (E) and
percentage of ingrowth area
vascularized (F) (n= 8). Color
images available online at
www.liebertonline.com/tea
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PU implanted in the same manner.4 Addition of heparin or
heparin plus growth factors resulted in a substantial increase
in vascularization at 10 days. Quantification for both vessel
number and area of ingrowth tissue vascularized showed
similar patterns. Delivery of VEGF in nonheparinized PU
discs did not increase vascularization of the scaffold. Addition
of heparin alone resulted in a significant increase in vessel
number (78%– 10%) and area vascularized (75%– 13%) over
that seen in unmodified PU. Loading of heparinized PU
with VEGF or VEGF plus PDGF-BB resulted in significant
increases in vessel number (VEGF: 19%– 5%; VEGF/PDGF-
BB 26%– 10%) and area vascularized (VEGF: 43%– 8%;
VEGF/PDGF-BB 46%– 9%) over that observed for heparin-
ized PU. This represents increases in vessel ingrowth for these
treatments relative to unmodified PU of 112%– 10% and
124%– 18% for VEGF and VEGF plus PDGF-BB, respectively.
Similarly area vascularized increased by 150%– 14% and
155%– 15%, respectively. There was no influence of PDGF-BB
bound to heparin on vascularization above that caused by the
addition of heparin. Additionally, the vascularization induced
by addition of both VEGF plus PDGF-BB to heparinized discs
was not significantly increased over that caused by addition of
VEGF alone.
Neovascularization after subcutaneous implantation
of heparinized porous PU for 2 months
The level of vascularization present within the treated and
untreated porous PU after 2 months was assessed in a similar
manner (Fig. 4). The vessels appeared similar in morphology
to that observed at 10 days, although there appeared to be a
greater proportion of smaller vessels. At 2 months, addition
of heparin alone now only resulted in a significant increase in
vessel number (72%– 26%) but not in area vascularized over
that in unmodified PU. Vascularization after loading of
heparinized PU with VEGF significantly increased above
that of PU alone for vessel number (110%– 24%) and area
vascularized (72% – 10%) but did not increase significantly
relative to heparinized PU. At 2 months, addition of PDGF-
BB or VEGF plus PDGF-BB did increase vascularization
relative to heparinized PU for vessel numbers (PDGF-BB:
69%– 17%; VEGF/PDGF-BB: 71% – 23%) and area vascular-
ized (PDGF-BB: 42%– 10%; VEGF/PDGF-BB: 43%– 13%).
These represent increases in vascularization for these treat-
ments relative to unmodified PU with numbers of vessels
being increased by 191%– 29% and 199%– 39% for PDGF-BB
and VEGF plus PDGF-BB, respectively. Similarly area vas-
cularized increased by 105%– 15% and 108%– 18%, respec-
tively. The vascularization induced by addition of VEGF plus
PDGF-BB was not significantly increased over that caused by
addition of PDGF-BB alone.
Arteriolization after subcutaneous implantation
of heparinized porous PU for 2 months
The 2-month implants were also assessed for arteriole
content by quantifying SMC actin-containing vessels (Fig. 5).
The 10 day explants had large populations of myofibroblasts
(data not shown) that precluded accurate analysis of arteriole
levels. Quantitation indicated that at 2 months all growth
factor containing treatments had a trend towards an increase
in arteriole numbers and area of ingrowth tissue occupied by
arterioles but that only the combination of VEGF plus PDGF-
BB was significantly elevated. The number of arterioles for
this group rose relative to heparinized PU by 66% – 22% and
the area occupied by arterioles by 68% – 16%.
Discussion
The heparin-based delivery system described here was
shown to be able to deliver two distinct growth factors at
markedly different rates. Utilizing this system in a quanti-
tative subcutaneous angiogenesis assay, it was further
demonstrated that there was a marked increase in vascu-
larization at 10 days for discs releasing VEGF from heparin,
with a further and substantial increase in response to PDGF-
BB observed only at 2 months. Importantly, the combination
of the two growth factors resulted in a sustained increase in
vascularization over the entire period.
The very similar amounts of each growth factor eluted
whether in the context of a single or dual loading of the two
factors on to the heparinised surface is possibly suggestive of
different binding sites being available for PDGF-BB and
VEGF. The substantially slower release kinetics of PDGF-BB
from heparin and its more efficient binding to the derivatized
surface in vitro presumably translated into PDGF-BB being
delivered for an extended period during implantation as
compared to VEGF.
The presence of a heparin surface alone on the PU discs
caused a significant increase in vessels at 10 days. This out-
come has been previously observed by us to persist out to 4
weeks in our model. In this present study, however, the vas-
cularization levels at 2 months indicate a potential diminish-
ment in the angiogenic response to the heparin surface alone
with only the number of vessels but not the area vascularized
being significantly increased. Heparin has been incorporated
into a variety of matrices and increased the angiogenic re-
sponse.16,21,22. Heparin modified fibrin,23 alginate,24 gelatin,25
and collagen matrices14 have all been reported to show similar
effects. The mechanism by which heparin stimulates vascu-
larization is not clear but it seems reasonable to suggest that it
may result form the trapping and stabilization of endoge-
nously released growth factors. It might be that at the later
time point there has been a general reduction in growth factor
production due to, for example, the resolution of the wound
healing associated inflammatory response26 and the observed
marked reduction in myofibroblasts.
The delivery of potent pro-angiogenic VEGF27 in conjunction
with heparin resulted in dramatic increases in vessel number
and area vascularized at 10 days relative to the unmodified PU
discs with the former doubling and the latter resulting in an
even more marked response. Although a significant proportion
of the VEGF was released during the wash steps in vitro and
thus a pronounced bolus effect would be expected in vivo, no
increase in vascularization was seen in unmodified discs loaded
with VEGF. This strongly suggests that sustained release is
needed for stimulated vessel ingrowth.4,11 However, the hepa-
rinized surface only allowed for a relatively short release period
for VEGF in vitro and it appears that release for an extended
period is required for persistent vessel presence.3,4 Thus, this is
a likely reason for the lack of a significant increase in vascu-
larization over heparinized discs at 2 months.
Delivery of PDGF-BB alone from heparinized surfaces did
not generate additional vessels at the earlier time point, but
by 2 months there was a significant increase above that
30 DAVIES ET AL.
FIG. 4. Vascularization





uncoated PU discs (A) and
heparin-coated PU discs
loaded with PDGF-BB (B) or
VEGF (C) or VEGF and PDGF-
BB (D) (bar represents 50 mm).
Vessel ingrowth was
quantified for both vessel
density (E) and percentage of
ingrowth area vascularized (F)
(n = 8). Color images available
online at www.liebertonline
.com/tea
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observed for heparinized discs alone. This increase was
considerable with the number of vessels triple that seen in
unmodified discs and the area vascularized having doubled.
There was not a significant increase in arterioles as might be
expected from this growth factor with its well-established
ability to recruit mural cells.28 A pronounced angiogenic
rather than an arteriogenic effect has not been generally
observed when PDGF-BB has been delivered either as a
gene29 or as a protein by controlled release from poly(lactide-
co-glycolide) discs.11 This indicates that the precise context of
delivery is of importance where in this study PDGF-BB was
most likely released at a very low dosage over an extended
period in the presence of heparin. A previous study that
delivered PDGF-BB from heparinized demineralised bone
scaffolds observed increased vessel levels above controls at
14 days postimplantation.15 However, the effect of the hep-
arin was not assessed, making it difficult to directly compare
these findings with ours. PDGF-BB has been shown to di-
rectly promote angiogenesis in vitro possibly via interaction
with its receptor PDGF-R beta that are present on endothelial
cells.30–32 Perhaps of greater relevance to this study is the
ability of PDGF-BB to induce increased expression of VEGF
from a variety of cells, including mural cells, endothelial
precursor cells, and tumor cells.33–36 It has been suggested
that PDGF-BB enhances glioma angiogenesis in part by in-
creasing VEGF expression33 and it has also been recently
shown that teratomas and embryoid bodies that have con-
stitutively activated PDGF-R beta have increased vasculari-
zation that could be blocked by neutralizing antibodies
against VEGF and its receptor VEGF-R2.37 Thus, it is possible
that prolonged release of low levels of PDGF-BB gradually
increased the levels of VEGF present in the disc and that this
VEGF may have been stabilized by the heparin surface.
The dual release of both growth factors resulted in ele-
vated levels at both time points but at levels similar to those
observed for VEGF at 10 days and PDGF-BB at 2 months.
There was therefore no indication of synergy for the two
factors and it is possible that the vessels observed at each
time point for the dual factor group resulted in each instance
from the angiogenic effect of the relevant individual factor.
However, there was a significantly increased level of arter-
iolization in this group at 2 months, suggestive of a persis-
tence of vessels that were induced earlier allowing for greater
mural cell investment. Similar results for arteriolization were
observed when these two growth factors were released to-
gether from poly-(lactide-co-glycide) sponges11; however, as
noted above there was no indication in this study of an an-
giogenic response to PDGF-BB.
Although vessel number remained relatively constant
between the two time points, the area vascularized had
FIG. 5. Arteriolization of tissue within porous PU discs after implantation for 2 months. Representative fluorescent mi-
crographs of a-smooth muscle cell actin immunostained explants of heparin-coated PU discs (A) and heparin-coated PU discs
loaded with VEGF and PDGF-BB (B) (bar represents 50 mm). Arrows and arrow heads indicate autofluorescing heparin
coating and putative erythrocytes/macrophages respectively. Arteriole ingrowth was quantified for both vessel density (C)
and percentage of ingrowth area vascularized (D) (n = 8). Color images available online at www.liebertonline.com/tea
32 DAVIES ET AL.
decreased from 6% at 10 days to 3.5% at 2 months. This
indicates a reduction in size as a result of vessel maturation
and might reflect increased intussusception of large vessels
and/or sprouting of smaller vessels.
In conclusion, surface modification of a well-defined
openly porous scaffold with heparin allows for a robust
means of exploring the angiogenic potential of a wide range
of heparin binding growth factors. In this particular study,
the staged release of VEGF and PDGF-BB resulted in a sus-
tained elevation of vascularization within a scaffold from as
early as 10 days to at least 2 months after implantation. The
growth factor-induced vascularization in this system appears
to be enhanced by the presence of the inherently pro-
angiogenic carrier, namely, heparin.
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